Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for pMMR/MSS mCRC
NCT07137390Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Bispecific Antibodies, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of lorigerlimab, regorafenib in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2025; status: withdrawn.
02
Drugs
lorigerlimabregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07137390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137390.